Neovasc Inc. Total Assets

Total Assets of NVCN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Total Assets growth rates and interactive chart. Total assets are the sum of all current and noncurrent assets and must equal the sum of total liabilities and stockholders' equity combined. In the accounting industry, assets are defined as anything that a business owns, has value, and can be converted to cash.


Highlights and Quick Summary

  • Total Assets for the quarter ending March 31, 2022 was $60 Million (a -8.84% decrease compared to previous quarter)
  • Year-over-year quarterly Total Assets decreased by -25.78%
  • Annual Total Assets for 2021 was $65.9 Million (a 267.27% increase from previous year)
  • Annual Total Assets for 2020 was $17.9 Million (a 77.91% increase from previous year)
  • Annual Total Assets for 2019 was $10.1 Million (a -24.68% decrease from previous year)
Visit stockrow.com/NVCN for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Total Assets of Neovasc Inc.

Most recent Total Assetsof NVCN including historical data for past 10 years.

Interactive Chart of Total Assets of Neovasc Inc.

Neovasc Inc. Total Assets for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $60.05
2021 $65.87 $71.99 $80.91 $89.98 $65.87
2020 $17.93 $18.79 $15.81 $11.56 $17.93
2019 $10.11 $15.13 $22.09 $16.09 $10.08
2018 $13.33 $17.38 $23.89 $16.13 $13.38
2017 $22.21 $81.76 $86.88 $91.99 $22.26
2016 $98.81 $0.0 $44.45 $54.53 $98.81
2015 $61.23 $70.54 $82.02 $86.92 $61.23
2014 $20.36 $25.28 $27.87 $29.26 $20.37
2013 $7.23 $8.78 $9.77 $8.3 $7.23
2012 $8.8 $4.69 $5.15 $5.76 $8.8
2011 $6.3 $6.3

Business Profile of Neovasc Inc.

Sector: Healthcare
Industry: Medical Devices
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include the Tiara technology for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008. Neovasc Inc. was incorporated in 2000 and is headquartered in Richmond, Canada.